1. Associations between use of cyclosporine-sparing agents and outcome in kidney transplant recipients 
Stephen P. Mcdonald, Graeme R. Russ 
Kidney International 
Volume 61, Issue 6, Pages (June 2002)
DOI: /j x
Copyright © 2002 International Society of Nephrology Terms and Conditions

2. Figure 1
Prevalence of cyclosporine-sparing agent (CsSpA) use by year of graft operation. Symbols are: () CsSpA; (▪) no CsSpA.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

3. Figure 2
Activity of each transplanting unit in Australia and New Zealand during study period, showing number of recipients of CsSpA. Symbols are () CsSpA; (▪) no CsSpA.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

4. Figure 3
Kaplan-Meier curves for graft survival (censored for patient death) for cadaveric donor (CD) recipients with and without diltiazem.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

5. Figure 4
Patient survival of CD recipients by CsSpA use at time of transplantation. The vertical line indicates one year after transplantation.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions